Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 5:M22-1300. doi: 10.7326/M22-1300

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article is made available via the PMC Open Access Subset for unrestricted re-use for research, analyses, and text and data mining through PubMed Central. Acknowledgement of the original source shall include a notice similar to the following: "© 2020 American College of Physicians. Some rights reserved. This work permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited." These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Visual Abstract. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in COVE. Antinucleocapsid antibodies (anti-N Abs) are currently being used to diagnose prior SARS-CoV-2 infection in individuals and to determine community seroprevalence of SARS-CoV-2. In a large, randomized, double-blind, placebo-controlled vaccine efficacy trial of the mRNA-1273 vaccine, anti-N Ab status was determined in participants who had prior SARS-CoV-2 infection confirmed by polymerase chain reaction or anti-N Abs. — Antinucleocapsid antibodies (anti-N Abs) are currently being used to diagnose prior SARS-CoV-2 infection in individuals and to determine community seroprevalence of SARS-CoV-2. In a large, randomized, double-blind, placebo-controlled vaccine efficacy trial of the mRNA-1273 vaccine, anti-N Ab status was determined in participants who had prior SARS-CoV-2 infection confirmed by polymerase chain reaction or anti-N Abs.